Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.
Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.
Why Is Eli Lilly Stock Falling Tuesday? Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.
MarketBeat Week in Review – 08/31 - 09/04 Stocks pulled back after a strong jobs report stoked rate-hike concerns. MarketBeat writers recap earnings-season themes, covering AI, cybersecurity, retail, energy, and dividend stocks.
Revolution Medicines Got Its Breakthrough—What Moves It Next? FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
If a Bear Market Is Coming, Is VOO or VTI the Safer Investment? You can't go wrong with either, but one has a key difference that gives it the edge.
Great News for Eli Lilly Stock Investors There is no end in sight for the company's incredible momentum.
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.
Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.
Vanguard Health Care ETF vs Simplify Health Care ETF Vanguard offers broad exposure at 0.09% cost with 1.5% yield, while Simplify's active strategy returned 32.4% over one year but charges 0.51%.
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.
3 Things That Matter Most for Eli Lilly Now Eli Lilly is the leader in the GLP-1 space, but the company can't rest on its laurels.
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.
